Please login to the form below

Not currently logged in
Email:
Password:

Elanco

This page shows the latest Elanco news and features for those working in and with pharma, biotech and healthcare.

GSK: we won’t be splitting up any time soon

GSK: we won’t be splitting up any time soon

The decision is in contrast to firms such as Novartis (selling its eyecare divison Alcon) and Lilly, which just announced the spin-off its animal health division Elanco.

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    For Lilly this is a good deal as it acquired the Novartis Animal Health business for $4.5bn last year and Elanco, its animal health business, is now said to be

  • Pharma deals during April 2014 Pharma deals during April 2014

    Animal health:. The Novartis Animal Health franchise transaction is the 8th and largest acquisition for Elanco, Lilly's Animal Health arm, since 2007 and catapults it to the global number 2

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    100. China Animal Health Care/ Elanco (Lilly). Part acquisition. Manufacturing, sale and distribution of animal drugs in China .

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics